Safety of Vericiguat in Patients with Coronary Artery Disease: A Systematic Review and Meta-analysis
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Vericiguat appears safe for coronary artery disease patients, showing minimal impact on vital signs. While serious adverse events were not significant, overall adverse events were higher compared to placebo.
Area Of Science
- Cardiology
- Pharmacology
- Clinical Trials
Background
- Coronary artery disease (CAD) management requires safe and effective therapies.
- Vericiguat is a medication under investigation for cardiovascular conditions.
- Assessing vericiguat's safety profile in CAD patients is crucial.
Purpose Of The Study
- To evaluate the safety and tolerability of vericiguat in patients with coronary artery disease.
- To conduct a meta-analysis of randomized controlled trials comparing vericiguat with placebo.
- To analyze adverse events associated with vericiguat treatment in this population.
Main Methods
- A comprehensive literature review was performed on PubMed, ClinicalTrials.gov, and Cochrane Library.
- Three randomized controlled trials involving 151 patients were included.
- Adverse events were analyzed using Review Manager software after quality assessment.
Main Results
- Vericiguat showed clinically insignificant changes in systolic blood pressure, diastolic blood pressure, and heart rate compared to placebo.
- No statistically significant serious adverse events were observed with vericiguat treatment.
- A statistically significant increase in overall adverse events was noted in the vericiguat group (OR = 4.04; P < 0.001).
Conclusions
- Vericiguat is suggested to be a safe medication for patients with coronary artery disease.
- Further clinical trials are warranted to confirm these safety findings.
- The increased incidence of adverse events requires careful consideration in clinical practice.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...